Toxin (comics)

IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio

Retrieved on: 
Vendredi, janvier 20, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Rosacea, Patient satisfaction, Tightness, Education, Face, HIT, World Congress, Hunger, PLLA, Safety, FDA, Skin, Food and Drug Administration, Toxin (comics), U.S. FDA, Food, Patient, Physician, Research, Congress, Dermatology, Science, STAR, Digital firm, Cheek, Chin, Hospital, Pharmaceutical industry, Cosmetics, Galderma, Sculptra

In addition, Galderma will share 10 research posters and host two symposia, featuring data from its broad, highly differentiated portfolio of neuromodulators, biostimulators and fillers.

Key Points: 
  • In addition, Galderma will share 10 research posters and host two symposia, featuring data from its broad, highly differentiated portfolio of neuromodulators, biostimulators and fillers.
  • Galderma is the only pure-play dermatology category leader, with more than 40 years of heritage in dermatology.
  • Results from the unique STAR study show high patient satisfaction, with most investigators preferring Alluzience to powder solutions.
  • HIT is a patient-centric, science-based, individualized treatment approach that enables injectors to leverage their expertise with the renowned Galderma portfolio and optimize aesthetic outcomes while prioritizing patient satisfaction.

AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine

Retrieved on: 
Mercredi, décembre 21, 2022
AEON, Migraine, Toxin (comics), Headache, Disability, SPAC, Smell, Sound, Injection, Vomiting, Disease, Nausea, Acquisition, Patient, Safety, Pharmaceutical industry

IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a private clinical-stage biopharmaceutical company focused on the development of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) for therapeutic indications, and Priveterra Acquisition Corp. (NASDAQ: PMGM) (“Priveterra”), a special purpose acquisition company (SPAC), today announced the completion of patient enrollment in the Phase 2 study of ABP-450 for the preventive treatment of episodic migraine. The Company expects to announce topline data from the study in the second half of 2023.

Key Points: 
  • “We are pleased to have completed patient enrollment in our Phase 2 episodic migraine study and look forward to releasing top-line data in the second half of next year,” said Marc Forth, AEON’s President and Chief Executive Officer.
  • Patients have at least a one-year history of episodic migraine (with or without aura) according to the ICHD-3 (2018) definition and diagnostic criteria.
  • All patients will receive two treatment cycles utilizing the Company’s novel treatment paradigm involving fewer injections than the current botulinum toxin treatment option for chronic migraine.
  • Migraine can be categorized as episodic migraine or chronic migraine.

Global Medical Aesthetics Technology is Seeing a Pinnacle of Growth: GoodFirms Research

Retrieved on: 
Mercredi, décembre 21, 2022
Research report, Patient, Medical tourism, Overalls, IOT, Obesity, Health, Growth, Aesthetics, Medicine, Face, Beauty, VR, AR, Ageing, CAD, Research, Artificial intelligence, Liposuction, Toxin (comics), Dentistry, Renewable energy, Medical imaging, Pharmaceutical industry, Health insurance, Telehealth

WASHINGTON, Dec. 21, 2022 /PRNewswire/ -- GoodFirms, a globally renowned research, ratings, and reviews platform, recently released its new research report - "Global Medical Aesthetics Market: Challenges, Trends, Scope, & Future." It aims to identify the key driving factors, top ongoing trends, and significant challenges in the medical aesthetics industry. The study also aims to uncover the future scope and opportunities in the Aesthetics technology.

Key Points: 
  • WASHINGTON, Dec. 21, 2022 /PRNewswire/ -- GoodFirms, a globally renowned research, ratings, and reviews platform, recently released its new research report - " Global Medical Aesthetics Market: Challenges, Trends, Scope, & Future ."
  • The research report from GoodFirms points out that the medical aesthetics industry provides ever-growing compelling options for people wanting to fulfill their beauty and health goals.
  • "In recent years, the market is seeing  a quick emergence of new medical aesthetics companies specializing in related products and services," says GoodFirms.
  • GoodFirms Survey-Global Medical Aesthetics Market, Challenges, Trends, Scope, & Future conducts a meticulous analysis of various global medical aesthetic industry dimensions.

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

Retrieved on: 
Mardi, décembre 13, 2022
AEON, Exhibit, Acquisition, BLA, Physician, Sub, Allergan, Neurology, Wardwell, Person, Security (finance), FDA, Reading, Sale, Economics, Prospectus, Latham & Watkins, Neurotoxin, Proxy, Atomic mass, Sumathi Best Television Current Reporting Award, Toxin (comics), History, Sustainability Accounting Standards Board, SPAC, Patient, Therapy, Form, Management, Pharmaceutical industry

Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".

Key Points: 
  • Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".
  • AEON has assembled a seasoned team with expertise in neuroscience research, development, regulatory affairs, operations, manufacturing, and commercialization.
  • Marc Forth, CEO and President of AEON Biopharma, said: “We’re making great progress across our late-stage clinical programs as we continue the development of ABP-450 for the treatment of multiple debilitating medical conditions.
  • AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.

EG 427 appoints Cornelia Haag-Molkenteller, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Mardi, novembre 29, 2022
Urology, D, Toxin (comics), R, Allergan, Biotechnology, Physician, Patient, Infection, Internal medicine, Research, Medical device, Pharmaceutical industry

Dr. Haag-Molkenteller is a board-certified urologist with over 30 years of global experience in clinical development and medical affairs.

Key Points: 
  • Dr. Haag-Molkenteller is a board-certified urologist with over 30 years of global experience in clinical development and medical affairs.
  • Cornelia will lead the clinical development strategy for our lead asset EG110A and our expanding pipeline.
  • "I am very excited to join EG 427 to support advancing options for patients and their treating physicians and health care providers across several areas with potential, truly novel therapies, explained Dr. Cornelia Haag-Molkenteller, now Chief Medical Officer at EG427.
  • She most recently served as Chief Medical Officer at Urovant Sciences, in California (USA), building up the R&D department and successful approval of the lead compound.

Global Botulinum Toxin Market Report 2022: Rising Demand for Non-Invasive and Minimally Invasive Cosmetic Procedures Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Jeudi, novembre 10, 2022
Cosmetics, Retail, Pharmaceutical, Health, People, Forehead, USD, Mouth, Marketing, Back pain, Cosmetics, Rash, Hyaluronic acid, Hair removal, BNT, Primary, Allergy, Chief executive officer, Man, VPS, MEA, Patient, Global, Growth, Woman, Clostridium botulinum, Neck, Nausea, Analysis, Toxin (comics), CAGR, Canning, D

However, opportunities for its therapeutic applications to expand the botulinum toxin market in the coming years are provided by significant investment in R&D initiatives.

Key Points: 
  • However, opportunities for its therapeutic applications to expand the botulinum toxin market in the coming years are provided by significant investment in R&D initiatives.
  • Top-down and bottom-up approaches were used to estimate and validate the size of the Global Botulinum Toxin Market and to estimate the size of various other dependent submarkets.
  • By type, the market is segmented into botulinum toxin type A, botulinum toxin type B.
  • Based on region the global botulinum toxin market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

THE AESTHETIC SOCIETY & THE AESTHETIC SURGERY EDUCATION AND RESEARCH FOUNDATION UNVEILS FINDINGS FROM THE BIOSPECIMEN STUDY ON BREAST IMPLANT ILLNESS (BII)

Retrieved on: 
Mercredi, novembre 9, 2022
Diagnosis, Lung, Bacteria, Face, Johns Hopkins University, Drug reaction with eosinophilia and systemic symptoms, Antibody, Brown University, News, Manuscript, Patient, Blood, MSJ, Capsule, Physician, Aesthetic Surgery Journal, Hematoma, American Board of Commissioners for Foreign Missions, International Conference on Information Systems Security and Privacy, Synthetic control method, Active Member, Plastic surgery, Breast implant, Royal college, Data analysis, BII, Histology, Immunology, Conference, Breast, Cytokine, Operation Time, Malignancy, Pathology, Royal College of Physicians and Surgeons of Canada, Surgeon, Woman, DNA, Neoplasm, Data collection, Social media, Research, Risk, Safety, Evidence-based medicine, Toxin (comics), Dentistry, Medical device, Birth control, Medical imaging, Ethics, MD, Enterotoxin

GARDEN GROVE, Calif., Nov. 9, 2022 /PRNewswire/ -- The Aesthetic Society and The Aesthetic Surgery Education and Research Foundation (ASERF) today released the findings from a study dedicated to researching the systemic symptoms self-reported by some breast implant patients, known as Breast Implant Illness. The Aesthetic Society is recognized as the world's leading member organization devoted entirely to aesthetic plastic surgery and cosmetic medicine of the face and body with 2,600 board-certified plastic surgeons in membership. ASERF is the philanthropic research and education arm of The Aesthetic Society. This study was funded entirely by an Aesthetic Surgery Education and Research Foundation (ASERF) grant awarded in 2019. There was no outside sponsor involvement in the research, data collection, data interpretation, data analysis, or writing of the manuscript. The full study is published in a peer-reviewed medical journal, the Aesthetic Surgery Journal.

Key Points: 
  • GARDEN GROVE, Calif., Nov. 9, 2022 /PRNewswire/ -- The Aesthetic Society and The Aesthetic Surgery Education and Research Foundation (ASERF) today released the findings from a study dedicated to researching the systemic symptoms self-reported by some breast implant patients, known as Breast Implant Illness.
  • This study was funded entirely by an Aesthetic Surgery Education and Research Foundation (ASERF) grant awarded in 2019.
  • The Aesthetic Society is at the forefront of innovation in aesthetic plastic surgery and cosmetic medicine globally.
  • Visit our website: www.theaestheticsociety.org
    The Aesthetic Surgery Education and Research Foundation (ASERF) is a 501(c)(3) not-for-profit charitable foundation.

Sensus Healthcare Reports Third Quarter 2022 Financial Results

Retrieved on: 
Jeudi, novembre 3, 2022
ROI, System, Company, Growth, Sale, GAAP, Finasteride, GLOBE, Tropical Storm Ian, Method, Conference, EBITDA, Vision, Tax, COVID-19, Nasdaq, Marketing, Income, EPS, Attention, Research, Adjustment, Conference call, Toxin (comics), TDI, Epidermis, Hyperhidrosis, SRT, Dermatology, Advertising, Depreciation, Patient, Pain, Medical imaging, Video game, Security (finance), Pharmaceutical industry, Bookkeeping

BOCA RATON, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2022.

Key Points: 
  • Revenues for the third quarter of 2022 were $9.0 million, compared with $5.5 million for the third quarter of 2021.
  • Cost of sales for the third quarter of 2022 was $3.1 million, compared with $2.3 million for the prior-year quarter.
  • Selling and marketing expense for the third quarter of 2022 was $1.8 million, compared with $1.2 million for the third quarter of 2021.
  • Adjusted EBITDA for the third quarter of 2022 was $2.3 million, compared with $0.5 million for the third quarter of 2021.

Merz Aesthetics® Announces Teyana Taylor as New Xeomin® (incobotulinumtoxinA) Brand Partner

Retrieved on: 
Mardi, novembre 1, 2022
Music, Other Health, Health, Women, Pharmaceutical, Entertainment, Celebrity, Men, Cosmetics, Retail, Consumer, People, Dizziness, Allergy, Breast milk, Skin infection, A Thousand and One Wives, Medication, Muscle, Color, Water, News, Partnership, Asthma, Time, Family, Risk, Botulism, Merz, Loyalty program, Rash, Regulation of tobacco by the U.S. Food and Drug Administration, Death, Merz Aesthetics Women's Challenger, Wheeze, Muscle weakness, Human, Safety, Injection, Beauty, Red, Swelling, Food, Medicine, Woman, FDA, Catherine Disher, Patient, Man, Multimedia, Music, Paramount Pictures, Skin care, Female, Eyebrow, Vitamin, Cosmetics, Health insurance, Pharmaceutical industry, Canning, Birth control, Toxin (comics), Toxin (comics)

Merz Aesthetics, the worlds largest dedicated medical aesthetics business, today announced Teyana Taylor as the latest Xeomin (incobotulinumtoxinA) brand partner.

Key Points: 
  • Merz Aesthetics, the worlds largest dedicated medical aesthetics business, today announced Teyana Taylor as the latest Xeomin (incobotulinumtoxinA) brand partner.
  • View the full release here: https://www.businesswire.com/news/home/20221101005084/en/
    Merz Aesthetics announces Teyana Taylor as new Xeomin (incobotulinumtoxinA) brand partner (Photo: Business Wire)
    I always strive to understand the ingredients in any product Im using and listen to trusted sources like my doctors when choosing whats right for my specific skin type, said 31-year-old Taylor.
  • The announcement of Taylor as the newest Xeomin brand partner is a part of the Beauty on Your Terms multi-channel campaign from Merz Aesthetics, which empowers women and men to embrace beauty on their own terms.
  • Teyana Taylor embodies the true meaning of Beauty on Your Terms through her music, her style and, now, her beauty treatments, said Patrick Urban, Merz Aesthetics President, North America.

hemotune Applauded by Frost & Sullivan for Enabling Selective and Efficient Extraction of Large Compounds from Blood With Its Blood Purification Platform

Retrieved on: 
Jeudi, octobre 27, 2022
Hemoperfusion, Frost & Sullivan, Technology, SAN, Antibody, Blood, Efficiency, Dialysis, Industry, Mortality, Patient, Frost, Cytokinesis, Achievement, Toxin (comics), Sepsis, Hospital, High-dependency unit, Creativity, Leadership, Death, Length of stay, Adsorption, Pharmaceutical industry, Medical imaging

SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ -- Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award. The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives. The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency. The system will be first used to treat sepsis, a severe life-threatening condition linked to 20% of all deaths and rising healthcare costs according to hemotune. Its solution focuses on the immunological aspects of sepsis, tackling multiple disease pathways while restoring immune balance.

Key Points: 
  • SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ --Recently, Frost & Sullivan assessed the blood purification technology industry and, based on its findings, recognizes hemotune with the 2022 Europe Technology Innovation Leadership Award.
  • The company developed a therapeutic blood purification platform to improve health outcomes and save patients' lives.
  • The innovative medical device company provides ground-breaking blood purification technology based on magnetic beads, which uniquely removes large biomolecule targets with extremely high selectivity and efficiency.
  • With its strong overall performance, hemotune earns Frost & Sullivan's 2022 Europe Technology Innovation Leadership Award in the blood purification technology market.